AstraZeneca, Daiichi Sankyo gets Chinese nod for Enhertu as first HER2-directed therapy for patients with HER2-low metastatic breast cancer

Enhertu is a HER2-directed ADC.

Related Keywords

China ,Peking ,Beijing ,United States ,Chinese ,American ,America ,Kiminori Nagao ,Binghe Xu ,Daiichi Sankyo ,Dave Fredrickson ,Department Of Medical Oncology ,Cancer Hospital Chinese Academy Of Medical Sciences ,China National Medical Products Administration ,Astrazeneca ,National Clinical Research Center ,American Society Of Clinical Oncology ,Union Medical College ,National Medical Products Administration ,American Society ,Clinical Oncology ,New England Journal ,New Anticancer Drugs ,Tenured Professor ,Former Director ,Medical Oncology ,Cancer Hospital Chinese Academy ,Medical Sciences ,Peking Union Medical College ,Executive Vice President ,Oncology Business Unit ,Central America ,Business Unit ,